研究者業績
  1. 研究者検索結果一覧
  2. 笹原 鉄平

笹原 鉄平

ササハラ テツペイ  (Teppei Sasahara)

基本情報

所属
自治医科大学 附属病院感染制御部 学内教授
学位
博士（医学）(自治医科大学)
M. D.(Sapporo Medical University)
研究者番号
30448849
J-GLOBAL ID
201401037468293772
researchmap会員ID
B000237798
外部リンク

研究キーワード

 5

研究分野

 1

経歴

 4

学歴

 2

受賞

 2

論文

 32
  • Dai Akine, Teppei Sasahara, Yuka Hirota, Hirotomo Kato
    The American journal of tropical medicine and hygiene 111(5) 953-955 2024年11月6日  
    Leishmaniasis is caused by an obligate intracellular protozoa of the genus Leishmania. Its clinical manifestations include cutaneous, mucocutaneous, and visceral forms. Sporotrichoid cutaneous leishmaniasis (SCL) is an atypical and rare form of cutaneous leishmaniasis (CL) reported mainly in the Old World. This case report describes SCL in a Japanese man infected with Leishmania (Viannia) peruviana in Peru. His lesions occurred on both feet, with the left foot lesion being a simple CL that resolved spontaneously. However, the lesion on the right foot did not cure by itself; instead, it progressed centrally along the lymph nodes, eventually forming an SCL. Amastigotes were detected in both feet and genetically identified as L. (V.) peruviana. The lesions gradually resolved after treatment with intravenous liposomal amphotericin B. Here, we report the first case of SCL caused by L. (V.) peruviana.
  • Feng-Yu Li, Xin-Ee Tan, Yuzuki Shimamori, Kotaro Kiga, Srivani Veeranarayanan, Shinya Watanabe, Yutaro Nishikawa, Yoshifumi Aiba, Yusuke Sato'o, Kazuhiko Miyanaga, Teppei Sasahara, Sarah Hossain, Kanate Thitiananpakorn, Tomofumi Kawaguchi, Huong Minh Nguyen, Adeline Yeo Syin Lian, Sharmin Sultana, Ola Alessa, Geoffrey Kumwenda, Jayathilake Sarangi, Jastin Edrian Cocuangco Revilleza, Priyanka Baranwal, Mohammad Omar Faruk, Yuya Hidaka, Myat Thu, Mahmoud Arbaah, Anujin Batbold, Maniruzzaman, Yi Liu, Ho Thi My Duyen, Takashi Sugano, Nayanjin Tergel, Takayuki Shimojyo, Longzhu Cui
    Communications biology 7(1) 1129-1129 2024年9月13日  
    In response to the escalating antibiotic resistance in multidrug-resistant pathogens, we propose an innovative phagemid-based capsid system to generate CRISPR-Cas13a-loaded antibacterial capsids (AB-capsids) for targeted therapy against multidrug-resistant Staphylococcus aureus. Our optimized phagemid system maximizes AB-capsid yield and purity, showing a positive correlation with phagemid copy number. Notably, an 8.65-fold increase in copy number results in a 2.54-fold rise in AB-capsid generation. Phagemids carrying terL-terS-rinA-rinB (prophage-encoded packaging site genes) consistently exhibit high packaging efficiency, and the generation of AB-capsids using lysogenized hosts with terL-terS deletion resulted in comparatively lower level of wild-type phage contamination, with minimal compromise on AB-capsid yield. These generated AB-capsids selectively eliminate S. aureus strains carrying the target gene while sparing non-target strains. In conclusion, our phagemid-based capsid system stands as a promising avenue for developing sequence-specific bactericidal agents, offering a streamlined approach to combat antibiotic-resistant pathogens within the constraints of efficient production and targeted efficacy.
  • Longzhu Cui, Shinya Watanabe, Kazuhiko Miyanaga, Kotaro Kiga, Teppei Sasahara, Yoshifumi Aiba, Xin-Ee Tan, Srivani Veeranarayanan, Kanate Thitiananpakorn, Huong Minh Nguyen, Dhammika Leshan Wannigama
    Antibiotics 13(9) 870-870 2024年9月11日  
    Phage therapy, the use of bacteriophages (phages) to treat bacterial infections, is regaining momentum as a promising weapon against the rising threat of multidrug-resistant (MDR) bacteria. This comprehensive review explores the historical context, the modern resurgence of phage therapy, and phage-facilitated advancements in medical and technological fields. It details the mechanisms of action and applications of phages in treating MDR bacterial infections, particularly those associated with biofilms and intracellular pathogens. The review further highlights innovative uses of phages in vaccine development, cancer therapy, and as gene delivery vectors. Despite its targeted and efficient approach, phage therapy faces challenges related to phage stability, immune response, and regulatory approval. By examining these areas in detail, this review underscores the immense potential and remaining hurdles in integrating phage-based therapies into modern medical practices.
  • Yuzuki Shimamori, Xin-Ee Tan, Feng-Yu Li, Yutaro Nishikawa, Shinya Watanabe, Teppei Sasahara, Kazuhiko Miyanaga, Yoshifumi Aiba, Srivani Veeranarayanan, Kanate Thitiananpakorn, Huong Minh Nguyen, Anujin Batbold, Tergel Nayanjin, Adeline Yeo Syin Lian, Sarah Hossain, Tomofumi Kawaguchi, Ola Alessa, Geofrey Kumwenda, Jayathilake Sarangi, Jastin Edrian C Revilleza, Priyanka Baranwal, Mahmoud Arbaah, Maniruzzaman, Liu Yi, Ho Thi My Duyen, Takashi Sugano, Sharmin Sultana, Mohammad Omar Faruk, Yuya Hidaka, Myat Thu, Takayuki Shimojyo, Kotaro Kiga, Longzhu Cui
    Scientific reports 14(1) 16225-16225 2024年7月13日  
    In response to the escalating global threat of antimicrobial resistance, our laboratory has established a phagemid packaging system for the generation of CRISPR-Cas13a-antimicrobial capsids targeting methicillin-resistant Staphylococcus aureus (MRSA). However, a significant challenge arose during the packaging process: the unintentional production of wild-type phages alongside the antimicrobial capsids. To address this issue, the phagemid packaging system was optimized by strategically incorporated silent mutations. This approach effectively minimized contamination risks without compromising packaging efficiency. The study identified the indispensable role of phage packaging genes, particularly terL-terS, in efficient phagemid packaging. Additionally, the elimination of homologous sequences between the phagemid and wild-type phage genome was crucial in preventing wild-type phage contamination. The optimized phagemid-LSAB(mosaic) demonstrated sequence-specific killing, efficiently eliminating MRSA strains carrying target antibiotic-resistant genes. While acknowledging the need for further exploration across bacterial species and in vivo validation, this refined phagemid packaging system offers a valuable advancement in the development of CRISPR-Cas13a-based antimicrobials, shedding light on potential solutions in the ongoing battle against bacterial infections.
  • Shinya Watanabe, Chijioke A. Nsofor, Kanate Thitiananpakorn, Xin-Ee Tan, Yoshifumi Aiba, Remi Takenouchi, Kotaro Kiga, Teppei Sasahara, Kazuhiko Miyanaga, Srivani Veeranarayanan, Yuzuki Shimamori, Adeline Yeo Syin Lian, Nguyen Minh Thuy, Huong Minh Nguyen, Ola Alessa, Geoffrey Kumwenda, Jayathilake Sarangi, Jastin Edrian C. Revilleza, Priyanka Baranwal, Yutaro Nishikawa, Li Feng-Yu, Tomofumi Kawaguchi, Sowmiya Sankaranarayanan, Mahmoud Arbaah, Zhang Yuancheng, Maniruzzaman, Liu Yi, Sarah Hossain, Li Junjie, Takashi Sugano, Ho Thi My Duyen, Anujin Batbold, Tergel Nayanjin, Longzhu Cui
    mBio e00339-24 2024年3月  
もっとみる

MISC

 50

書籍等出版物

 6
もっとみる

講演・口頭発表等

 36
もっとみる

担当経験のある科目(授業)

 3

所属学協会

 8
もっとみる

共同研究・競争的資金等の研究課題

 3
一覧へ戻る